Immunopeptidomics Patents

Immunopeptidomics patents cover MHC-isolation/mass-spec innovations; prediction-algorithm innovations; target-discovery/antigen innovations; and dataset/platform and validation/application innovations — with IP held by immunotherapy companies, antigen-discovery firms, and academia (in a field identifying the peptides cells display to the immune system). WHY IMMUNOPEPTIDOMICS: the immune system's T cells don't recognize whole proteins — they see short PEPTIDES (about 8-11 amino acids) that cells chop their proteins into and PRESENT on the surface bound to MHC (in humans, HLA) molecules; the complete set of these displayed peptides is the 'IMMUNOPEPTIDOME'; to attack cancer with T-cell-based therapies (TCR-T cell therapies, cancer vaccines, bispecific T-cell engagers), you MUST target a peptide that tumor cells ACTUALLY DISPLAY on their surface — but computationally PREDICTING which peptides get presented is unreliable, and targeting a peptide that isn't actually presented wastes years; IMMUNOPEPTIDOMICS directly MEASURES the presented peptidome — it isolates the MHC/HLA molecules from cells or tumors and uses sensitive MASS SPECTROMETRY to sequence the bound peptides, revealing the TRUE targets (including unexpected ones from non-canonical sources), de-risking immunotherapy target selection. MAJOR HOLDERS: BIONTECH, GENENTECH, IMMATICS, AGENUS, plus academia and mass-spec vendors. MHC isolation/mass spec, prediction algorithms, target discovery/antigen, dataset/platform, and validation/application are the core immunopeptidomics patent domains — with §101 to manage on natural sequences/correlations, and mass-spec methods, prediction, target discovery, datasets, and validation the open whitespace.

MHC-isolation/mass-spec innovations; prediction-algorithm innovations; sensitivity/throughput innovations; and §101-aware claiming represent core immunopeptidomics patent domains — and the experimental method that reads the peptidome and the algorithms that predict it are the foundational, high-value capabilities. MHC-ISOLATION / MASS-SPEC PATENTS: the wet-lab METHOD — IMMUNOPRECIPITATING MHC/HLA complexes from cells/tumors (capturing the molecules with their bound peptides), eluting the peptides, and sequencing them by sensitive MASS SPECTROMETRY — plus sample prep, enrichment, and the analytical workflow; MHC-isolation/mass-spec methods are core, high-value IP (this experimental technology is the heart of immunopeptidomics — a clearly-patentable technical process, and the method that turns a tumor into a list of presented peptides is foundational). PREDICTION-ALGORITHM PATENTS: COMPUTATIONAL PREDICTION of which peptides a given HLA binds and presents (and how they're processed and whether they're immunogenic) — machine-learning MODELS trained on binding/presentation data (NetMHC-style and successors); prediction-algorithm methods are high-value IP BUT §101-SENSITIVE (claim a specific technical model/system or an integrated discovery method, not the abstract idea of 'predicting binding'). SENSITIVITY / THROUGHPUT PATENTS: improving the SENSITIVITY (presented peptides are scarce — often very few copies per cell, so detecting them pushes mass-spec limits) and throughput of the measurement; sensitivity/throughput methods are high-value, distinctive IP (sensitivity is the central technical challenge — detecting rare presented peptides, especially low-abundance neoantigens, is what determines how many real targets you find). §101-AWARE CLAIMING: a naturally-presented peptide is a natural product and its disease correlation a natural law — claim the METHOD, the engineered binder/therapy targeting it, or a specific technical process; §101-aware claiming is essential. MHC isolation/mass spec, prediction algorithms, sensitivity/throughput, and §101-aware claiming are the highest-value core IP because a sensitive experimental method plus accurate prediction — claimed around §101 — is exactly what reveals the true immunotherapy targets.

Target-discovery/antigen innovations; dataset/platform innovations; validation/application innovations; and non-canonical-antigen innovations represent additional immunopeptidomics patent domains — and finding tumor-specific targets, the data/model moat, and applying targets to therapies are where the value and whitespace lie. TARGET-DISCOVERY / ANTIGEN PATENTS: finding tumor-SPECIFIC presented PEPTIDES that make good immunotherapy targets — NEOANTIGENS (from tumor mutations), CANCER-TESTIS antigens, and tumor-associated antigens — and characterizing them; target/antigen discovery methods are high-value IP, with the specific peptide/target §101-AWARE (a naturally-presented peptide is a natural product — protect the discovery METHOD, the engineered therapy (TCR/vaccine/bispecific) targeting it, and use claims, rather than the peptide per se). DATASET / PLATFORM PATENTS: PROPRIETARY immunopeptidome DATASETS (large collections of measured presented peptides across HLA types and tissues) and the integrated discovery PLATFORM (combining mass spec + prediction + validation); dataset/platform value is high BUT often best protected as a TRADE-SECRET/data asset (a large, high-quality immunopeptidome dataset and the models trained on it are a major, hard-to-replicate moat — frequently more valuable than patents, and data isn't directly patentable). VALIDATION / APPLICATION PATENTS: CONFIRMING a target is genuinely PRESENTED and IMMUNOGENIC (T cells respond to it), and APPLYING discovered targets to TCR-T cell therapies, cancer VACCINES (overlaps neoantigen vaccines), and BISPECIFIC T-cell engagers; validation/application methods and the resulting therapies are high-value IP (the engineered therapy targeting a validated antigen is the patentable product). NON-CANONICAL-ANTIGEN PATENTS: discovering 'DARK'/non-canonical antigens (from non-coding regions, frameshifts, splice variants) that prediction misses but mass spec finds — a distinctive whitespace; non-canonical-antigen methods are high-value, distinctive IP (non-canonical antigens are a frontier mass spec uniquely reveals — rich, defensible territory). Target discovery/antigen, dataset/platform, validation/application, and non-canonical antigens are the highest-value application IP because finding validated, tumor-specific (including non-canonical) targets and turning them into therapies — claimed around §101 — is exactly what makes immunopeptidomics valuable.

Immunopeptidomics startup IP strategy must navigate the §101 natural-product/correlation limit (a naturally-presented peptide is a natural product and its disease link a natural law — protect the discovery METHOD, the engineered therapy targeting the antigen, and use claims, not the peptide per se), the data-is-the-moat reality (a large, high-quality proprietary immunopeptidome DATASET and the prediction models trained on it are often the biggest, hardest-to-replicate advantage — best protected as trade-secret/data, frequently more valuable than patents), the method-vs-target distinction (the mass-spec METHOD and platform are clearly patentable technical IP; specific targets are §101-limited but the engineered therapies targeting them are patentable products), the sensitivity-is-everything insight (detecting rare presented peptides, especially low-abundance neoantigens, is the central technical challenge and a key differentiator), the prediction/§101 sensitivity (ML prediction must be claimed as a technical system/method), the platform-vs-therapeutic strategy (be a discovery PLATFORM/data company selling targets to partners, or develop your own therapies — different IP/business), the non-canonical-antigen whitespace (mass spec uniquely finds 'dark' antigens prediction misses — a frontier), the application overlap (targets feed TCR therapies, vaccines, and bispecifics — overlaps those fields), and a landscape where mass-spec methods, prediction, target discovery, datasets, and validation are the durable assets; understand that targets are §101-limited and data is key, so the durable IP is in mass-spec/isolation methods, sensitivity/throughput, prediction (as systems), the immunopeptidome dataset (trade-secret), and engineered therapies/use claims — with the dataset, platform, sensitivity, and validated targets often the real moat, and that sensitivity, data/platform, validated targets, §101-survivable claiming, and clinical relevance matter as much as patents; identify whitespace in sensitivity, non-canonical antigens, prediction, and datasets. IMMUNOPEPTIDOMICS STARTUP IP STRATEGY: MASS-SPEC/ISOLATION METHODS, SENSITIVITY, PREDICTION (AS SYSTEMS), DATASET (TRADE-SECRET), AND ENGINEERED THERAPIES/USE CLAIMS ARE THE IP: patent MHC-isolation/mass-spec methods, sensitivity/throughput, prediction (as technical systems), and engineered therapies/use claims targeting validated antigens — protect the dataset as trade-secret; §101 LIMITS THE TARGET (NATURAL PRODUCT): a naturally-presented peptide is a natural product and its disease link a natural law — protect the discovery METHOD, the engineered therapy, and use claims, not the peptide per se; DATA IS THE MOAT — TRADE-SECRET IT: a large, high-quality proprietary immunopeptidome dataset + the models trained on it are the biggest, hardest-to-replicate advantage — often more valuable than patents, and data isn't directly patentable; METHOD VS TARGET — THE METHOD IS CLEARLY PATENTABLE: the mass-spec/isolation method and platform are clear technical IP; targets are §101-limited but engineered therapies targeting them are patentable products; SENSITIVITY IS EVERYTHING: detecting rare presented peptides (esp. low-abundance neoantigens) is the central technical challenge and a key differentiator; PREDICTION IS §101-SENSITIVE: claim ML prediction as a technical system/method, not the abstract idea; PLATFORM VS THERAPEUTIC STRATEGY: be a discovery platform/data company (sell targets to partners) or develop your own therapies — different IP/business; NON-CANONICAL ('DARK') ANTIGENS ARE THE WHITESPACE: mass spec uniquely finds antigens prediction misses (non-coding/frameshift/splice) — a frontier; APPLICATION OVERLAP: targets feed TCR therapies, neoantigen vaccines, and bispecifics; SENSITIVITY/DATA/VALIDATED-TARGETS/§101/CLINICAL MATTER AS MUCH AS PATENTS: sensitivity, data/platform, validated targets, §101-survivable claiming, and clinical relevance drive value; WHEN TO PATENT (OR TRADE-SECRET): NOVEL METHOD/SENSITIVITY/PREDICTION/THERAPY WITH MEASURED PERFORMANCE: file (or trade-secret the dataset) once a method shows measured results (mass-spec sensitivity/peptides detected + prediction accuracy + tumor-specific target yield + target presentation/immunogenicity validation + (therapy) efficacy) — measured sensitivity, validated-target yield, and the dataset are the critical immunopeptidomics IP metrics; KEY FTO CHECKLIST: BioNTech/Genentech/Immatics/Agenus + academia/mass-spec vendors; §101 natural-product (claim method/therapy/use, not the peptide); MHC isolation/mass spec (immunoprecipitation/elution/sequencing workflow); prediction algorithm (HLA binding/presentation/immunogenicity ML — §101); sensitivity/throughput (rare peptide detection); target discovery/antigen (neoantigen/cancer-testis/non-canonical — §101); dataset/platform (immunopeptidome data + models — trade-secret); validation/application (presentation/immunogenicity confirmation; TCR/vaccine/bispecific — overlaps those fields); non-canonical/'dark' antigens; platform-vs-therapeutic.